

Right ventricular contractility decreases during exercise in patients with non-advanced idiopathic pulmonary fibrosis

Sandra Cobra¹, Marcelo Palmeira Rodrigues², Felipe Xavier de Melo³, Nathali Mireise Costa Ferreira², and César Augusto Melo-Silva⁴

¹Hospital de Base do Distrito Federal

²School of Medicine University of Brasília

³University Hospital of Brasília

⁴University of Brasília

August 23, 2020

Abstract

Introduction: Early right ventricular dysfunction in non-advanced patients with idiopathic pulmonary fibrosis has not been fully elucidated. Thus, we aimed to assess right ventricular functions in idiopathic pulmonary fibrosis patients and controls by speckle-tracking strain echocardiography at rest and peak exercise. **Methods:** We conducted a cross-sectional study in 20 idiopathic pulmonary fibrosis patients without oxygen use, blood oxygen saturation levels $[?]92\%$ at rest, and modified Medical Research Council score $[?]3$ and enrolled ten matched controls. Transthoracic echocardiography images were acquired at rest and during a cardiopulmonary exercise test. We assessed two-dimensional echocardiographic parameters and right ventricular function using the global longitudinal strain assessed by the two-dimensional speckle-tracking technique. **Results:** In the control group, we found normal values of global longitudinal strain (GLS) at rest and at peak exercise, the latter being much more negative ($-23.6 \pm 2.2\%$ and $-26.8 \pm 3.1\%$, respectively; $p < 0.001$). By contrast, GLS values in the idiopathic pulmonary fibrosis group increased from $-21.1 \pm 3.8\%$ at rest to $-17.0 \pm 4.5\%$ at peak exercise ($p < 0.001$). The exercise revealed a difference between the two groups as the mean GLS values moved during peak exercise in opposite directions. Patients with idiopathic pulmonary fibrosis worsened, whereas control patients experienced improved right ventricular contractility. **Conclusions:** Right ventricular dysfunction was unveiled by speckle-tracking echocardiography during exercise in non-advanced idiopathic pulmonary fibrosis patients. We suggest that this reflects an inadequate right ventricular-arterial coupling decreasing the right ventricular longitudinal contraction during exercise in these patients. This parameter may be useful as an early index of suspected pulmonary hypertension.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible chronic lung disease [1]. Pulmonary hypertension (PH) is common in advanced IPF [2,3] and increases the risk of death by approximately threefold [4]. The prevalence varies between 3-86% but is most commonly 30-50% [5].

Typically, some IPF outcomes are related to PH and the adaptation of the right ventricle (RV) to the afterload changes. In these cases, RV failure components may drive mortality [6]. Despite its critical relevance, RV function remains unclear in these patients, particularly in those without severe hypoxemia at rest. Patients with non-advanced IPF and PH are probably the best study candidates to increase our understanding of “disproportional PH.”

Ventriculoarterial uncoupling is the physiological consequence of failing RV adaptation. The gold standard for assessing ventriculoarterial coupling is invasive, involving cardiac catheterization; however, it is difficult to assess during exercise, as it requires manipulation of the venous return [7]. Two-dimensional transthoracic echocardiography (2D TTE) allows a complementary investigation of RV behaviors in diverse pulmonary disease stages. D’Andrea et al., used RV speckle-tracking echocardiography (STE) to evaluate the global longitudinal strain (GLS), and demonstrated that RV STE is an accurate tool for the evaluation of right ventricular function, is easy to perform, and feasible in various clinical scenarios of RV dysfunction [8].

Evaluation of exercise-induced changes in pulmonary hemodynamics may improve understanding on pulmonary circulation-heart interactions. The analysis of RV function during exercise can predict RV failure in IPF [9]. Minor myocardial dysfunction emerging from abnormal systolic contractility can be accurately and non-invasively measured by STE [10] and may even be detected with minor afterload changes [11].

Data are lacking on RV dysfunction at rest and during exercise in patients at early IPF stages with normal or near-normal oxyhemoglobin peripheral saturation (SpO_2). D’Andrea et al. described RV dysfunction during exercise using STE [12]; however, they included patients with severe hypoxemia at rest (mean SpO_2 , 83%) and probably patients at advanced IPF stages.

To date, there are no approved medications available for treating PH in these patients [13]. Evaluating pulmonary circulation-heart interactions and RV functions through ventricular-vascular coupling is a powerful approach that should improve understanding on the disease. Singh et al. demonstrated that RV-pulmonary artery dissociation could compromise RV contractility in response to increased afterloads during exercise [14]. This increased afterload is probably insufficient to maintain a normal cardiac output and will eventually result in the deterioration of RV-pulmonary artery (PA) coupling at peak exercise.

We hypothesized that increased PA pressure and consequent RV dysfunction may occur at early IPF stages as part of its development. We also hypothesized that STE can detect RV function impairments during exercise even in IPF patients without RV dysfunction at rest, and could serve as an early index for suspected PH.

Methods

This study was approved by the Ethics Committee of School of Medicine - University of Brasília – Brazil (protocol number CAAE: 71022817.2.0000.5558) and written informed consent was obtained from all subjects. The procedures in this research were in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 1983.

We evaluated 116 consecutive IPF patients between February and December 2017 who were diagnosed according to the criteria of the American Thoracic Society and European Respiratory Society [15]. Treatment for interstitial lung diseases followed in a tertiary care center at the University Hospital of Brasília. Among 116 subjects, we selected 20 for 2D TTE at rest and cardiopulmonary exercise testing (CPET); 2D TTE was performed as per the American Society of Echocardiography guidelines [16].

Inclusion criteria for IPF patients included a Gender-Age-Physiology Index score [?]5, compatible with mild or moderate disease [17], modified Medical Research Council scale [18] score [?]3, and SpO_2 [?]92% at rest and in room air without oxygen therapy. Patients with locomotor diseases, severe comorbidities (e.g., lung cancer, pulmonary thromboembolism, and stroke), left cardiomyopathy, or combined emphysema and pulmonary fibrosis were excluded.

Controls were recruited from elderly healthy family members and friends of the IPF patients. The subjects of the control group were strictly matched for similar age and gender to IPF patients. We selected 10 subjects to this group in order to achieve one control subject to every two IPF patients. The controls did not demonstrate respiratory symptoms, had no history of lung diseases, and did not meet the same exclusion criteria of IPF patients.

Transthoracic Doppler echocardiography at rest

The baseline resting echocardiogram before CPET was performed using a Vivid I (GE Healthcare, Milwaukee, WI, USA). Final values were obtained after averaging over three cardiac cycles. Conventional echocardiographic parameters were acquired to evaluate RV functions. The modified Bernoulli equation was applied to calculate systolic PA pressure (sPAP) from tricuspid regurgitation. The formula $mPAP = 0.61 \times sPAP + 2$ mmHg was used [19], assuming that sPAP equaled the right systolic ventricular pressure in the absence of RV-pulmonary stenosis or outflow tract obstruction [20]. The estimated right atrial pressure was based on the inferior vena cava collapsibility index, which was added to the sPAP [16, 21]. Images were adjusted for better RV free wall delimitation and STE analysis.

RV function assessment by 2D TTE and STE

The STE technique [22] was applied to images using the EchoPac software (v. 201; General Electric, Vingmed, Horten, Norway) offline. The beginning and end of the RV systole were defined using the event-timing feature of this software to evaluate RV GLS. Regions of interest were marked manually, and RV free wall edges were adjusted to enable adequate tracing of basal, medial, and apical portions of the RV myocardium. This was performed at both rest and peak exercise; images were adjusted for better delimitation of the RV free wall endocardium (Figs 1–3). The average of three segments defined the measurement results. The systolic peak longitudinal strain reflecting muscle fiber contraction was expressed as a percentage and has a negative value [22]. Current reference values for global RV free wall STE suggest that values [?]-20% are normal [16].

CPET with simultaneous echocardiography

All participants were tested using an incremental ramp protocol. A cycle ergometer (CG-04; Inbramed^(r), Porto Alegre, RS, Brazil) was used with a progressively increasing load. The protocol consisted of pedaling for 1 min at 60 rotations/min without load (0 W). The load was then increased in 5-W steps from 5 to 30 W/min. As per the American Thoracic Society recommendations [23], we recorded the dyspnea level, exercise capacity, maximum predicted value of oxygen extraction ($V'O_2$), and patient age. These parameters were analyzed during an incremental load period of 8-12 min. The effort was considered to be maximal if the subject achieved predicted $V'O_2$ with a plateau, predicted maximal heart rate, respiratory exchange ratio greater than 1.15, ventilatory limitation or BORG scale rating of 9-10.

Cardiovascular and ventilatory variables were assessed once all expiratory gas measurements at each breath had been documented (Quark PFT; Cosmed, Rome, Italy). Pulse oximetry findings (Ipod^(r); Nonin Medical, Inc., Plymouth, MN, USA), heart rates, and electrocardiographic parameters were continuously recorded. $V'O_2$ released CO_2 ($V'CO_2$), CO_2 pressures, volume expired per minute ($V'E$), and final expiratory O_2 were registered every 15 sec. The auscultatory method was employed to record systolic and diastolic blood pressures at all load increases. The gas exchange method allowed non-invasive estimation of the anaerobic threshold [23]. Equal scales, which include the V-slope technique (slope of the $V'O_2$ versus $V'CO_2$ graph), were used to analyze this parameter. To determine the performance of ventilatory equivalents ($V'E/V'CO_2$ and $V'E/V'O_2$) and their final expiratory pressures [23], the ventilatory method was used, validating the V-slope technique.

The BORG effort perception scale [24] was applied to evaluate muscle fatigue sensations and dyspnea during CPET, and echocardiography images were obtained to identify tricuspid regurgitation better [16]. Simultaneous images were stored every minute for the offline sPAP analysis.

During the recovery period, tricuspid regurgitation spectral traces were recorded for 3-4 minutes.

Statistical analysis

Normal distribution was confirmed by the Kolmogorov-Smirnov test for all continuous variables. The data are presented as the mean±standard deviation, and 95% confidence intervals (95% CIs) are shown. Student's *t*-test for independent samples was used to compare means of continuous variables. Categorical variables are presented as percentages. We used the chi-squared test to compare proportions. Analyses between GLS measures and CPET variables was calculated using Pearson correlations. Data were analyzed using SPSS for Mac OS X^(c) (v.25.0.0; SPSS, Inc., Chicago, IL, USA). Results were considered statistically significant at $p < 0.05$.

Data

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Results

The study population comprised 30 participants: 10 controls and 20 patients with IPF. Table 1 summarizes the demographic, echocardiographic, and pulmonary function test data at baseline. The two groups did not differ in terms of sex ($p = 0.605$) and age ($p = 0.219$).

As seen in Table 1, with regard to conventional TTE parameters, the following variables presented significant differences between groups: RV fractional area ($p < 0.001$), left atrial volume ($p = 0.011$), and tricuspid annular plane systolic excursion ($p = 0.012$). However, the mean values and all the individuals' values in those three variables were within normal range. There were no significant differences between the study groups in terms of right atrial volume ($p = 0.199$), Mitral E/E' (mitral valve E velocity by mitral annular E' velocity ratio) values for left ventricular end diastolic pressure ($p = 0.458$) and peak tissue Doppler imaging values of the lateral tricuspid systolic annulus velocity ($p = 0.695$).

As seen in Table 2, the resting mPAP difference, determined by echocardiography, was higher in the IPF group than in controls ($p = 0.008$). As expected, mPAP values increased during exercise in both groups. However, peak exercise mPAP values were even higher in IPF patients ($p = 0.015$).

Echocardiographic data revealed that in the control group, all participants had normal GLS values at rest and at peak exercise, the latter demonstrating considerably greater negativity ($-23.6 \pm 2.16\%$ and $-26.8 \pm 3.1\%$, respectively, 95% CI: 2.0 to 4.4, $p < 0.001$). This indicates that the RV contractility had increased overall. Differently, in the entire IPF group, GLS values changed from $-21.1 \pm 3.8\%$ at rest to $-17.0 \pm 4.5\%$ at peak exercise (95% CI: 2.1 to 6.1, $p < 0.001$), which indicates that the RV contractility mean had decreased. During exercise, only three IPF patients presented slightly improved RV contractility; from rest to peak exercise, their values changed as follows: -14.5 to -19.6 , -16.0 to -18.0 , and -16.8 to -18.0 .

IPF patients could be divided into two groups: (1) normal GLS at rest with decreased RV contractility during exercise; (2) abnormal GLS at rest that also worsened with exercise. In this first subgroup, the 12 IPF patients (60%) with normal GLS values at rest ($-23.49 \pm 2.91\%$) declined during exercise ($-18.23 \pm 4.62\%$, 95% CI: 3.5 to 6.9, $p < 0.001$). In this second subgroup, eight IPF patients (40%) had abnormal GLS values at rest ($-17.70 \pm 1.85\%$) that worsened at peak exercise ($-15.27 \pm 4.14\%$, 95% CI: -2.3 to 7.1, $p = 0.266$), however, this difference did not achieve statistical significance.

Comparing IPF patients with controls, GLS values were only found to be significantly different at peak exercise (controls: $-17.0 \pm 4.5\%$, IPF: $-26.8 \pm 3.1\%$, 95% CI: -13.1 to -6.5, $p < 0.001$; Table 2). The difference in GLS at rest between IPF patients and controls was not statistically significant ($-21.1 \pm 3.8\%$ and $-23.6 \pm 2.1\%$, respectively, 95% CI: -5.1 to 0.2, $p < 0.068$). Importantly, the mean GLS values of the two groups moved in opposite directions during exercise (Fig 4). On STE analyses, RV contractility worsened in IPF

patients, and improved in controls. GLS differences between the two groups were also more apparent at peak exercise.

We also performed a correlation analysis between the main CPET variables and GLS values both at rest and at peak exercise. Most Pearson correlation coefficients demonstrated a weak-to-moderate correlation (Table 3); mainly those that referred to GLS at peak exercise were statistically significant. All patients and all subjects in the control group were made to exercise until exertion. IPF patients achieved lower $\dot{V}O_2$ peak compared to controls (16.4 \pm 3.2 and 24.6 \pm 7.5 mL/Kg/min, respectively, 95% CI: 2.7 to 13.7, $p<0.007$); lower O_2 pulse (8.4 \pm 2.3 and 12.0 \pm 4.2 mL/Kg/min/beat, respectively, 95% CI: 0.3 to 6.6, $p<0.031$); and lower maximal heart rate (125 \pm 15 and 143 \pm 11 beats/min, respectively, 95% CI: 6.5 to 29.5, $p<0.003$).

Discussion

CPET in combination with STE was suitable for studying RV function in IPF patients. Our findings demonstrated that GLS measured by STE during exercise was capable of unveiling systolic RV dysfunction in non-advanced IPF patients, although RV function measurements at rest by conventional echocardiography were similar between IPF and control groups. Exercise-induced changes in STE may provide an early index for suspected PH in non-advanced IPF stages.

In this study, we found that as measured by STE, the RV function in IPF patients failed to increase appropriately during exercise. In contrast, the RV contractility in controls improved to more negative GLS values. Exercise results in pulmonary hemodynamic changes, elevating the PA pressure due to an increase in cardiac output [25]. In healthy subjects, passive distension of the pulmonary circulation and vasodilation-mediated flow changes accommodate this cardiac output with modest mPAP increases and decreased pulmonary vascular resistance [26]. Thus, the RV adapts to increased afterload by increasing contractility.

Our main finding is that IPF patients at non-advanced stages already have an impaired RV contractile reserve. The failure to improve RV contractility in response to a progressive rise in afterload probably results from poor RV-PA coupling at peak exercise. We speculate that GLS STE values at rest do not predict the success or failure to improve RV contractility during exertion, i.e., to uncover contractility changes, it must be measured during exercise.

Unmasking pulmonary vascular disease by raising the cardiac output to demonstrate an increase in pulmonary resistance is a logical idea. In contrast to left ventricular fibers, the predominant longitudinal orientation of RV fibers may minimize the mechanisms that preserve RV systolic function during increased afterload [7]. Furthermore, a thinner RV wall is capable of accommodating an increased preload; however, it is inadequate for greatly increased PA pressures [27]. This may explain the RV dysfunction at peak exercise detected by GLS STE in non-advanced IPF patients.

Additionally, we observed a correlation lack between CPET parameters and STE measurements at rest in the IPF group. However, we found a moderate correlation between STE RV functions and most parameters at peak exercise, supporting the importance of STE measurements during exercise for understanding patients' physiological changes. A notable and significant correlation was detected between GLS and SpO_2 during exercise. This indicates subclinical hypoxia as a possible cause for PH and RV dysfunction, even in non-advanced, non-hypoxemic patients at rest, and may be due to SpO_2 decreases during exercise and/or sleep [28].

Several studies attempted to uncover pulmonary vascular disease by redistributing the flow or increasing the cardiac output utilizing echocardiography with exercise stress [29] or dobutamine administration [30]. Nowadays, these approaches have poor applicability and low reliability. The present study suggests that non-advanced IPF patients have associated RV dysfunction with increased mPAP during exercise. As PH

progresses, RV synchrony is lost. Intraventricular asynchrony may be present even in early disease stages [31]. Thus, RV function can be temporarily suppressed at peak exercise, returning to baseline values at rest.

We also compared RV function and pulmonary hemodynamic responses in control subjects and found that exercise stress was associated with a lower mPAP slope, and improved RV contractility. Only a few studies assessed changes in RV function during exercise in healthy subjects. Exercise echocardiography was compared with exercise cardiac magnetic resonance imaging and invasive pressure measurements. They suggested that echocardiography during exercise represents an efficient screening tool to identify RV function changes and pulmonary vascular disease [9].

The current study has some limitations. First, 2D TTE was used to non-invasively assess intracardiac pressure instead of direct measurements using catheterization; however, hemodynamic invasive measurements are not appropriate for patients without advanced IPF. Second, at present there is no specific software for RV STE analysis, and, for this study, we used the software that measures LV function.

There are also questions regarding the interpretation of our findings. First, GLS STE during exercise may offer an early warning marker of global RV dysfunction and may predict the outcome or functional capacity in IPF patients better than STE at rest. Second, as abnormalities in RV functions and PH are present at early disease stages, and are not exclusively caused by hypoxia, other factors may contribute to the development of PH and RV dysfunction.

Conclusion

Exercise echocardiography may assess RV function in non-advanced IPF patients. Exercise unmasks RV dysfunction, which decreases when an acute overload likely promotes RV-PA uncoupling. Patients with impaired RV function should receive greater attention as this parameter may be an early index of suspected PH and may indicate poorer prognosis.

Declarations

Authors' contributions: SBC analyzed and interpreted patient data and was a major contributor to the manuscript preparation. MPR reviewed all data and made substantial contributions to the conception and design of the work. FXM acquired and analyzed CPET data. NMCF selected all patients. CAMS acquired and analyzed the data and revised the work. All authors have read and approved the final manuscript.

Acknowledgments:

The authors especially want to thank Lauro Casqueiro Vianna, PhD, from NeuroVASQ-Integrative Physiology Laboratory (University of Brasilia) for providing the ultrasound equipment to execute the exams. We would like to thank Editage for English language editing.

References

1. Lederer DJ, Martinez FJ: Idiopathic Pulmonary Fibrosis. *N Engl J Med* 2018;378(19):1811-1823.
2. Nadrous HF, Pellikka PA, Krowka MJ, et al: Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. *Chest* 2005;128(4):2393-2399.
3. Lettieri CJ, Nathan SD, Barnett SD, et al: Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. *Chest* 2006;129(3):746-752.
4. Patel NM, Lederer DJ, Borczuk AC, et al: Pulmonary hypertension in idiopathic pulmonary fibrosis. *Chest* 2007;132(3):998-1006.
5. Raghu G, Amatto VC, Behr J, Stowasser S: Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. *Eur Respir J* 2015;46(4):1113-1130.

6. Rivera-Lebron BN, Forfia PR, Kreider M, et al: Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. *Chest* 2013;144(2):564-570.
7. Tran DL, Lau EMT, Celermajor DS, et al: Pathophysiology of exercise intolerance in pulmonary arterial hypertension. *Respirology* 2018;23(2):148-159.
8. D'Andrea A, Stanziola A, Di Palma E, et al: Right Ventricular Structure and Function in Idiopathic Pulmonary Fibrosis with or without Pulmonary Hypertension. *Echocardiography* 2016;33(1):57-65.
9. Claessen G, La Gerche A, Voigt JU, et al: Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise. *JACC Cardiovasc Imaging* 2016;532-543.
10. Giusca S, Dambrauskaite V, Scheurwegs C, et al: Deformation imaging describes right ventricular function better than longitudinal displacement of the tricuspid ring. *Heart* 2010;96(4):281-288.
11. Rajagopal S, Forsha DE, Risum N, et al: Comprehensive assessment of right ventricular function in patients with pulmonary hypertension with global longitudinal peak systolic strain derived from multiple right ventricular views. *J Am Soc Echocardiogr* 2014;27(6):657-665.e3.
12. D'Andrea A, Stanziola AA, Saggar R, et al: Right Ventricular Functional Reserve in Early-Stage Idiopathic Pulmonary Fibrosis: An Exercise Two-Dimensional Speckle Tracking Doppler Echocardiography Study. *Chest* 2019;155(2):297-306.
13. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. *N Engl J Med* 2010;363(7):620-628.
14. Singh I, Rahaghi FN, Naeije R, et al: Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension. *Pulm Circ* 2019;2045894019862435.
15. Raghu G, Collard HR, Egan JJ, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;183(6):788-824.
16. Lang RM, Badano LP, Mor-Avi V, et al: Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging [published correction appears in *Eur Heart J Cardiovasc Imaging* 2016;17(4):412] [published correction appears in *Eur Heart J Cardiovasc Imaging* 2016;17(9):969]. *Eur Heart J Cardiovasc Imaging*. 2015 16(3):233-270.
17. Ley B, Ryerson CJ, Vittinghoff E, et al: A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med* 2012;156(10):684-691.
18. Papiris SA, Daniil ZD, Malagari K, et al: The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. *Respir Med* 2005;99(6):755-761.
19. Chemla D, Castelain V, Provencher S, et al: Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. *Chest* 2009;135(3):760-768.
20. Abbas AE, Fortuin FD, Schiller NB, et al: A simple method for noninvasive estimation of pulmonary vascular resistance. *J Am Coll Cardiol* 2003;41(6):1021-1027.
21. Rudski LG, Lai WW, Afilalo J, et al: Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr* 2010;23(7):685-713.
22. Leitman M, Lysyansky P, Sidenko S, et al: Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. *J Am Soc Echocardiogr* 2004;17(10):1021-1029.
23. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2003;167(2):211-277.
24. Borg GA. Perceived exertion. *Exerc Sport Sci Rev* 1974;2:131-153.
25. Lewis GD, Bossone E, Naeije R, et al: Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. *Circulation* 2013;128(13):1470-1479.
26. Domingo E, Grignola JC, Aguilar R, et al: Impairment of pulmonary vascular reserve and right

- ventricular systolic reserve in pulmonary arterial hypertension. BMC Pulm Med 2014: 24;14:69.
27. Sanz J, Sanchez-Quintana D, Bossone E, et al: Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;2;73(12):1463-1482.
 28. Rodrigues MP, Vissoci CM, Rosa SP, et al: 24-Hour Hypoxia and Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis. Open Respir Med J 2017;29;11:10-16.
 29. Lau EM, Manes A, Celermajer DS, et al: Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J 2011;32(20):2489-2498.
 30. Lau EMT, Vanderpool RR, Choudhary P, et al: Dobutamine stress echocardiography for the assessment of pressure-flow relationships of the pulmonary circulation. Chest 2014;146(4):959-966.
 31. Lamia B, Muir JF, Molano LC, et al: Altered synchrony of right ventricular contraction in borderline pulmonary hypertension. Int J Cardiovasc Imaging 2017;33(9):1331-1339.

Tables

Table 1. Demographic and echocardiographic data of the IPF and control groups at rest

Variable ^a	IPF ^b (n=20)	Control (n=10)	95% CI of difference	P
Age (year)	72.3 ± 8.6	68.5 ± 5.2	-9.8 to 2.3	0.219
Sex (Female/Male)	10/10	6/4		0.619
SpO ₂ rest (%)	93.2 ± 1.6	94.1 ± 1.4	-0.03 to 2.43	0.056
FVC%	67.1 ± 15.2	-	-	-
FEV ₁ %	74.3 ± 11.7	-	-	-
D _L CO%	53.9 ± 19.0	-	-	-
LA (mL/m ²)	20.8 ± 6.2	14.7 ± 4.4	-10.5 to -1.4	0.011
RA (mL/m ²)	15.5 ± 5.8	12.5 ± 5.6	-7.5 to 1.6	0.199
RV FAC (%)	46.8 ± 9.9	62.0 ± 7.6	7.8 to 22.4	<0.001
RV TAPSE (mm)	20 ± 3	22 ± 2	0.4 to 5.1	0.012
TDI RV Sm peak (cm/s)	12 ± 2	13 ± 2	1.0 to 1.6	0.695
sPAP (mmHg)	33.4 ± 10.8	22.8 ± 7.1	-18.4 to -2.8	0.009
mPAP (mmHg)	21.8 ± 6.2	15.4 ± 4.5	-10.9 to -1.7	0.008
E/E' average	7.7 ± 1.9	7.2 ± 1.3	-1.9 to 0.8	0.458

^a*D_LCO%* carbon monoxide diffusing capacity of the lung, *E/E'* mitral E/E' ratio, *FEV₁%* forced expiratory volume in 1 s as a percentage of the predicted value, *FVC%* forced vital capacity as a percentage of the predicted value, *IPF* idiopathic pulmonary fibrosis, *LA* left atrium, *mPAP* mean PA pressure, *RA* right atrium, *RV FAC* right ventricle fractional area change, *sPAP* systolic PA pressure, *SpO₂* peripheral oxyhemoglobin saturation, *TAPSE* tricuspid annular plane systolic excursion, *TDI RV Sm peak* tissue Doppler imaging of lateral tricuspid systolic annulus velocity

^bData are presented as the mean ± standard deviation

Table 2. Echocardiographic data at rest and their corresponding exercise parameters

Variable ^a	IPF ^b (n=20)	Control ^b (n=10)	95% CI of difference	p
mPAP (at rest, mmHg)	21.8 ± 6.2	15.4 ± 4.5	-10.9 to -1.7	0.008
mPAP (peak exercise, mmHg)	42.4 ± 16.0	28.0 ± 9.8	-25.7 to -2.9	0.015

Variable ^a	IPF ^b (n=20)	Control ^b (n=10)	95% CI of difference	p
mPAP (peak – rest, mmHg)	20.6 ± 11.8	12.6 ± 7.6	-16.4 to 0.4	0.001
GLS% (at rest)	-21.1 ± 3.8	-23.6 ± 2.1	-5.1 to 0.2	0.068
GLS% (peak)	-17.0 ± 4.5	-26.8 ± 3.1	-13.1 to -6.5	<0.001
GLS% (peak) - GLS% (at rest)	4.1	-3.2	-10.2 to -4.4	<0.001

^aGLS global longitudinal strain, IPF idiopathic pulmonary fibrosis, mPAP mean PA pressure

^bData are presented as the mean ± standard deviation

Table 3. Pearson correlation coefficients between CPET data and GLS values

Variable ^a	GLS% at rest	P	GLS% at peak exercise	P
V'O ₂ peak	-0.164	0.388	-0.458	0.011 ^b
V'O ₂ peak (%)	-0.205	0.277	-0.462	0.010 ^b
V'O ₂ AT	-0.283	0.130	-0.470	0.009 ^b
V'O ₂ AT/V'O ₂ predicted	-0.176	0.352	-0.345	0.062
O ₂ pulse (V'O ₂ /HR)	-0.339	0.067	-0.419	0.021 ^b
V'E/V'CO ₂ (peak)	0.234	0.213	0.412	0.024 ^b
V'E/V'CO ₂ (slope)	0.122	0.520	0.372	0.043 ^b
V'E/V'CO ₂ (AT)	0.277	0.139	0.480	0.007 ^b
PETCO ₂ (peak)	-0.231	0.220	-0.369	0.045 ^b
PETCO ₂ (AT)	-0.183	0.332	-0.389	0.034 ^b
V'E maximal (L/min)	-0.167	0.378	-0.353	0.056
V'E/MVV	-0.125	0.510	-0.071	0.709
SpO ₂ (rest)	-0.144	0.448	-0.154	0.416
SpO ₂ (peak)	-0.233	0.215	-0.501	0.005 ^b
BORG (dyspnea)	0.042	0.827	0.322	0.089
BORG (leg fatigue)	0.140	0.470	0.019	0.923

AT anaerobic threshold, BORG BORG scale score, CPET cardiopulmonary exercise test, GLS global longitudinal strain, HR heart rate, PETCO₂ end-expiratory CO₂ partial pressure, SpO₂ oxyhemoglobin saturation, V'O₂ AT oxygen consumption anaerobic threshold, V'O₂ peak peak exercise oxygen consumption, V'O₂AT/V'O₂ predicted oxygen consumption anaerobic threshold/oxygen consumption predicted, V'E maximal maximal volume expired per minute, V'E/MVV volume expired per minute/maximum voluntary ventilation, V'E/V'CO₂ volume expired per minute/CO₂ ventilation

^b Statistically significant

Figure Legends

Fig 1 Normal global longitudinal strain (GLS%) obtained at rest in a patient with IPF

Fig 2 Abnormal global longitudinal strain (GLS%) obtained at peak exercise in the same patient with IPF

Fig 3 Normal global longitudinal strain (GLS%) obtained at rest and at peak of exercise in the control group

Fig 4 Right ventricular systolic strain shifts from rest to peak exercise in control participants and patients with IPF





